Axonics (MEX:AXNX) Short-Term Debt : MXN0 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Axonics Short-Term Debt?

Axonics's Short-Term Debt for the quarter that ended in Mar. 2024 was MXN0 Mil.

Axonics's annual Short-Term Debt increased from Dec. 2021 (MXN0 Mil) to Dec. 2022 (MXN636 Mil) but then declined from Dec. 2022 (MXN636 Mil) to Dec. 2023 (MXN0 Mil).

Axonics Short-Term Debt Historical Data

The historical data trend for Axonics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics Short-Term Debt Chart

Axonics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

419.92

635.57

Axonics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Axonics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Axonics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Axonics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Axonics (MEX:AXNX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (MEX:AXNX) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

AXNX:USA

Address

26 Technology Drive, Irvine, CA, USA, 92618

Website

https://www.axonics.com

Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.